The pharmacological management of depression – Update 2017
Depression affects nearly 350 million people worldwide. Local data indicates that approximately 17% of all South Africans will experience at least one episode of depression in their lifetime. Depressive disorders contribute significantly towards overall morbidity and increased risk for suicide. Anti...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
AOSIS
2017-03-01
|
Series: | South African Family Practice |
Subjects: | |
Online Access: | https://safpj.co.za/index.php/safpj/article/view/4625 |
id |
doaj-05c5d74712c144ffb5c80d8a93e6b05f |
---|---|
record_format |
Article |
spelling |
doaj-05c5d74712c144ffb5c80d8a93e6b05f2020-11-25T02:53:10ZengAOSISSouth African Family Practice2078-61902078-62042017-03-0159161610.4102/safp.v59i1.46253703The pharmacological management of depression – Update 2017Elzbieta Osuch0Andre Marais1Sefako Makgatho Health Sciences UniversityUniversity of PretoriaDepression affects nearly 350 million people worldwide. Local data indicates that approximately 17% of all South Africans will experience at least one episode of depression in their lifetime. Depressive disorders contribute significantly towards overall morbidity and increased risk for suicide. Antidepressant therapy remains one of the cornerstones in the management of depressive disorders. Although the efficacy of antidepressive drugs is continuously subjected to criticism, thousands of controlled clinical trials have shown, and will continue to show, their benefit in the effective treatment of depressive disorders. Since the introduction of antidepressants in the early 1950s, researchers have been searching for an ideal antidepressant able to adequately reduce, preserve and prevent features of depression with the absence of side effects. This article summarizes the currently available antidepressant drugs in South Africa. Discontinued products have been omitted and newly registered agents have been added. This review does not contain reference to any experimental drug, or substances not yet available for local use.https://safpj.co.za/index.php/safpj/article/view/4625major depressive disorderantidepressantserotoninnoradrenalinedopamine |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Elzbieta Osuch Andre Marais |
spellingShingle |
Elzbieta Osuch Andre Marais The pharmacological management of depression – Update 2017 South African Family Practice major depressive disorder antidepressant serotonin noradrenaline dopamine |
author_facet |
Elzbieta Osuch Andre Marais |
author_sort |
Elzbieta Osuch |
title |
The pharmacological management of depression – Update 2017 |
title_short |
The pharmacological management of depression – Update 2017 |
title_full |
The pharmacological management of depression – Update 2017 |
title_fullStr |
The pharmacological management of depression – Update 2017 |
title_full_unstemmed |
The pharmacological management of depression – Update 2017 |
title_sort |
pharmacological management of depression – update 2017 |
publisher |
AOSIS |
series |
South African Family Practice |
issn |
2078-6190 2078-6204 |
publishDate |
2017-03-01 |
description |
Depression affects nearly 350 million people worldwide. Local data indicates that approximately 17% of all South Africans will experience at least one episode of depression in their lifetime. Depressive disorders contribute significantly towards overall morbidity and increased risk for suicide. Antidepressant therapy remains one of the cornerstones in the management of depressive disorders. Although the efficacy of antidepressive drugs is continuously subjected to criticism, thousands of controlled clinical trials have shown, and will continue to show, their benefit in the effective treatment of depressive disorders. Since the introduction of antidepressants in the early 1950s, researchers have been searching for an ideal antidepressant able to adequately reduce, preserve and prevent features of depression with the absence of side effects. This article summarizes the currently available antidepressant drugs in South Africa. Discontinued products have been omitted and newly registered agents have been added. This review does not contain reference to any experimental drug, or substances not yet available for local use. |
topic |
major depressive disorder antidepressant serotonin noradrenaline dopamine |
url |
https://safpj.co.za/index.php/safpj/article/view/4625 |
work_keys_str_mv |
AT elzbietaosuch thepharmacologicalmanagementofdepressionupdate2017 AT andremarais thepharmacologicalmanagementofdepressionupdate2017 AT elzbietaosuch pharmacologicalmanagementofdepressionupdate2017 AT andremarais pharmacologicalmanagementofdepressionupdate2017 |
_version_ |
1724726279568097280 |